
A late-stage trial of GlaxoSmithKline’s investigational Crohn’s disease drug failed to benefit patients. The SHIELD-1 study was investigating vercirnon – …
Boyds expands Regulatory Affairs team to support growing demand
Sterling doubles ADC manufacturing capacity at Welsh facility
Femtosecond laser cuts lung tumour margin assessment time
Blood sensor detects Parkinson’s-associated proteins in 40 minutes

